Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | BLM | P54132 | 3/20 | 0.35 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.35 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.35 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 5/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2841384 | 1.00 | KMT2A (0.45) | KMT2AMEN1BLMGABRR1GABRR2 | |
| SCHEMBL15709422 | 0.83 | HCAR2 (0.43) | KMT2AMEN1BLMPMP22HSD17B10 | |
| SCHEMBL15709423 | 0.83 | HCAR2 (0.43) | KMT2AMEN1BLMPMP22HSD17B10 | |
| SCHEMBL2842616 | 0.83 | PIK3CD (0.38) | KMT2AMEN1BLMGABRR1GABRR2 | |
| SCHEMBL2842621 | 0.83 | PIK3CD (0.38) | KMT2AMEN1BLMGABRR1GABRR2 | |
| Hydrochloric Acid SCHEMBL15709160 | 0.81 | PIK3CD (0.37) | KMT2AMEN1BLMGABRR1GABRR2 | |
| Hydrochloric Acid SCHEMBL15709158 | 0.81 | PIK3CD (0.37) | KMT2AMEN1BLMGABRR1GABRR2 | |
| SCHEMBL20711789 | 0.80 | MEN1 (0.38) | KMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL29003331 | 0.80 | PIK3CD (0.36) | KMT2AMEN1BLMGABRR1GABRR2 | |
| SCHEMBL20416122 | 0.78 | TSHR (0.39) | BLMGABRR1GABRR2GABRR3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2253620-A1 | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors | Wyeth Holdings Corporation (US) | 2010-11-24 | — | — | EP | claimed |
| EP-1950201-A1 | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors | Wyeth Holdings Corporation (US) | 2008-07-30 | — | — | EP | claimed |
| EP-1117649-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | American Cyanamid Company (US) | 2001-07-25 | — | — | EP | claimed |
| WO-2000018740-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-04-06 | — | — | WO | claimed |
| CN-116157388-A | Carbocyclic amide derivative and application thereof in medicine | 四川海思科制药有限公司 | 2023-05-23 | — | — | CN | disclosed |
| WO-2022053000-A1 | CARBOCYCLIC AMIDE DERIVATIVE AND APPLICATION THEREOF IN MEDICINE | 四川海思科制药有限公司 | 2022-03-17 | — | — | WO | disclosed |
| US-9540385-B2 | Pyrrolopyrimidine compounds as kinase inhibitors | PHARMACYCLICS LLC (US) | 2017-01-10 | — | — | US | disclosed |
| US-9540385-B2 | Pyrrolopyrimidine compounds as kinase inhibitors | PHARMACYCLICS LLC (US) | 2017-01-10 | — | — | US | disclosed |
| US-9540385-B2 | Pyrrolopyrimidine compounds as kinase inhibitors | PHARMACYCLICS LLC (US) | 2017-01-10 | — | — | US | disclosed |
| US-20160375026-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. | 2016-12-29 | — | — | US | disclosed |
| US-20160375026-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. | 2016-12-29 | — | — | US | disclosed |
| EP-2920180-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | Pharmacyclics, Inc. (US) | 2015-09-23 | — | — | EP | disclosed |
| US-9062058-B2 | — | — | 2015-06-23 | — | — | US | disclosed |
| WO-2014078578-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| WO-2014078578-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| US-20140142126-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142126-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142126-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| EP-2253620-B1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | WYETH HOLDINGS LLC (US) | 2014-03-12 | — | — | EP | disclosed |
| EP-2253620-A1 | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors | Wyeth Holdings Corporation (US) | 2010-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160375026-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | BTK, LCK, ZAP70 | KMT2A 1705/4885MEN1 4737/4885BLM 1450/4885 |
| US-20140142126-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | BTK, LCK, LYN | KMT2A 1302/4885MEN1 4342/4885BLM 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.